Literature DB >> 9192741

Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum.

Y Yatomi1, Y Igarashi, L Yang, N Hisano, R Qi, N Asazuma, K Satoh, Y Ozaki, S Kume.   

Abstract

Although sphingosine 1-phosphate (Sph-1-P) is reportedly involved in diverse cellular processes and the physiological roles of this bioactive sphingolipid have been strongly suggested, few studies have revealed the presence of Sph-1-P in human samples, including body fluids and cells, under physiological conditions. In this study, we identified Sph-1-P as a normal constituent of human plasma and serum. The Sph-1-P levels in plasma and serum were 191+/-79 and 484+/-82 pmol/ml (mean+/-SD, n=8), respectively. Furthermore, when Sph-1-P was measured in paired plasma and serum samples obtained from 6 healthy adults, the serum Sph-1-P/plasma Sph-1-P ratio was found to be 2.65+/-1.26 (mean+/-SD). It is most likely that the source of discharged Sph-1-P during blood clotting is platelets, because platelets abundantly store Sph-1-P compared with other blood cells, and release part of their stored Sph-1-P extracellularly upon stimulation. We also studied Sph-1-P-related metabolism in plasma. [3H]Sph was stable and not metabolized at all in plasma, but was rapidly incorporated into platelets and metabolized mainly to Sph-1-P in platelet-rich plasma. [3H]Sph-1-P was found to be unchanged in plasma, revealing that plasma does not contain the enzymes needed for Sph-1-P degradation. In summary, platelets can convert Sph into Sph-1-P, and are storage sites for the latter in the blood. In view of the diverse biological effects of Sph-1-P, the release of Sph-1-P from activated platelets may be involved in a variety of physiological and pathophysiological processes, including thrombosis, hemostasis, atherosclerosis and wound healing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192741     DOI: 10.1093/oxfordjournals.jbchem.a021681

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  118 in total

1.  Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3.

Authors:  H Okamoto; N Takuwa; T Yokomizo; N Sugimoto; S Sakurada; H Shigematsu; Y Takuwa
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Sphingosine 1-phosphate activates Weibel-Palade body exocytosis.

Authors:  Kenji Matsushita; Craig N Morrell; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

3.  The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice.

Authors:  Shigetomo Fukuhara; Szandor Simmons; Shunsuke Kawamura; Asuka Inoue; Yasuko Orba; Takeshi Tokudome; Yuji Sunden; Yuji Arai; Kazumasa Moriwaki; Junji Ishida; Akiyoshi Uemura; Hiroshi Kiyonari; Takaya Abe; Akiyoshi Fukamizu; Masanori Hirashima; Hirofumi Sawa; Junken Aoki; Masaru Ishii; Naoki Mochizuki
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 4.  Shaping the landscape: metabolic regulation of S1P gradients.

Authors:  Ana Olivera; Maria Laura Allende; Richard L Proia
Journal:  Biochim Biophys Acta       Date:  2012-06-23

5.  Fluid shear stress and sphingosine 1-phosphate activate calpain to promote membrane type 1 matrix metalloproteinase (MT1-MMP) membrane translocation and endothelial invasion into three-dimensional collagen matrices.

Authors:  Hojin Kang; Hyeong-Il Kwak; Roland Kaunas; Kayla J Bayless
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

6.  Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells.

Authors:  Sonja Balthasar; Johanna Samulin; Hanna Ahlgren; Nina Bergelin; Mathias Lundqvist; Emil C Toescu; Margaret C Eggo; Kid Törnquist
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

7.  BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P(3).

Authors:  M Jongsma; M C Hendriks-Balk; M C Michel; S L M Peters; A E Alewijnse
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

8.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

9.  Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins.

Authors:  J Igarashi; M Miyoshi; T Hashimoto; Y Kubota; H Kosaka
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

Review 10.  Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling.

Authors:  Emmanuel Eroume A Egom; Yunbo Ke; R John Solaro; Ming Lei
Journal:  Prog Biophys Mol Biol       Date:  2010-01-18       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.